Company Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113.
Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
| Country | United States |
| Founded | 2006 |
| IPO Date | Aug 11, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 112 |
| CEO | Dr. Dinesh V. Patel Ph.D. |
Contact Details
Address: 7707 Gateway Blvd., Suite 140 Newark, California 94560-1160 United States | |
| Phone | (510) 474-0170 |
| Website | protagonist-inc.com |
Stock Details
| Ticker Symbol | PTGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001377121 |
| CUSIP Number | 74366E102 |
| ISIN Number | US74366E1029 |
| Employer ID | 98-0505495 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Dinesh V. Patel Ph.D. | Chief Executive Officer, President, Secretary and Director |
| Dr. Suneel K. Gupta Ph.D. | Chief Development Officer |
| Dr. Mark Smythe Ph.D. | Founder and Vice President Technology |
| Asif Ali | Executive Vice President and Chief Financial Officer |
| Mohammad Masjedizadeh Ph.D. | Executive Vice President and Chief Technical Officer |
| Matthew M. Gosling | Executive Vice President and General Counsel |
| Carena Spivey | Head of Human Resources and Senior Vice President of Human Resources |
| Dr. Ashok Bhandari Ph.D. | Executive Vice President and Chief Drug Discovery and Preclinical Development Officer |
| Carter J. King | Executive Vice President of Business Development |
| Abha Bommireddi | Executive Vice President of Portfolio and Program Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 1, 2024 | 144 | Filing |
| Mar 1, 2024 | 144 | Filing |
| Mar 1, 2024 | 144 | Filing |
| Mar 1, 2024 | 144 | Filing |
| Feb 29, 2024 | 144 | Filing |
| Feb 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2024 | 10-K | Annual Report |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |